Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. [Review] (Record no. 4943)

MARC details
000 -LEADER
fixed length control field 03348nam a22005657a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200210s20192019 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1947-6108
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.14797/mdcj-15-4-250 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC6977568 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 31988685
245 ## - TITLE STATEMENT
Title Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. [Review]
251 ## - Source
Source Methodist DeBakey cardiovascular journal. 15(4):250-257, 2019 Oct-Dec.
252 ## - Abbreviated Source
Abbreviated source Methodist Debakey Cardiovasc J. 15(4):250-257, 2019 Oct-Dec.
252 ## - Abbreviated Source
Former abbreviated source Methodist Debakey Cardiovasc J. 15(4):250-257, 2019 Oct-Dec.
253 ## - Journal Name
Journal name Methodist DeBakey cardiovascular journal
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2019
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2020
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
266 ## - Date added to catalog
Date added to catalog 2020-02-10
268 ## - Previous citation
-- Methodist DeBakey cardiovascular journal. 15(4):250-257, 2019 Oct-Dec.
520 ## - SUMMARY, ETC.
Abstract Tumor-targeted therapies such as trastuzumab have led to significant improvements in survival of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, these therapies have also been associated with significant left ventricular dysfunction. The incidence of trastuzumab-induced heart failure has decreased significantly since the initial reports, in large part due to improved screening, closer monitoring for early changes in left ventricular function, and a significant decrease in the concurrent administration of anthracyclines. The mechanism of trastuzumab cardiotoxicity is still not well understood, but current knowledge suggests that ErbB2 inhibition in cardiac myocytes plays a key role. In addition to trastuzumab and other HER2-targeted agents, vascular endothelial growth factor inhibitors, proteasome inhibitors, and immune checkpoint inhibitors are all additional classes of drugs used with great success in the treatment of solid tumors and hematologic malignancies. Yet these, too, have been associated with cardiac toxicity that ranges from a mild asymptomatic decrease in ejection fraction to fulminant myocarditis. In this review, we summarize the cardiotoxic effects of tumor-targeted and immunotherapies with a focus on HER2 antagonists. Copyright (c) 2019 Houston Methodist Hospital Houston, Texas.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Antineoplastic Agents, Immunological/ae [Adverse Effects]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Heart Failure/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Immunotherapy/ae [Adverse Effects]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Molecular Targeted Therapy/ae [Adverse Effects]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Animals
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cardiotoxicity
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Heart Failure/ep [Epidemiology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Heart Failure/pp [Physiopathology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Heart Failure/th [Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prognosis
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Risk Assessment
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Risk Factors
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Heart & Vascular Institutena
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Union Memorial Hospital
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Cardio-Oncology
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Internal Medicine
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Agunbiade, Tolulope A
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Barac, Ana
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Zaghlol, Raja
790 ## - Authors
All authors Agunbiade TA, Barac A, Zaghlol RY
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.14797/mdcj-15-4-250">https://dx.doi.org/10.14797/mdcj-15-4-250</a>
Public note https://dx.doi.org/10.14797/mdcj-15-4-250
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 02/10/2020   31988685 31988685 02/10/2020 02/10/2020 Journal Article

Powered by Koha